Evidence for improving the therapeutic response to ixekizumab: more than just a statistic

The availability of biotechnological drugs, increasingly targeted to pivotal mediators of pathogenesis of psoriasis, has significantly improved the therapeutic perspectives as well as the quality of life of patients with psoriasis. The use of this class of molecules for more than a decade allows them to be considered safe, even in long‐term, continuous treatment. A multicenter, phase III randomized trial showed that the increase in dosing frequency significantly improves ixekizumab efficacy without affecting the safety profile of the treatment provides evidence for strengthening its therapeutic potential.